Interdisciplinary Prostate Cancer Congress | Conference

Dr. Sandler on the Unique Characteristics of Radium-223

March 27th 2013

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Dr. Gomella on Sequencing Prostate Cancer Therapies

March 25th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

Dr. Petrylak on Sipuleucel-T Delaying First Opioid Use

March 21st 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on Combination Therapies in Prostate Cancer

March 20th 2013

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Dr. Crawford Discusses Active Surveillance in Prostate Cancer

March 19th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Dr. Slovin on Prostate Cancer Immunotherapy Evolution

March 18th 2013

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

New Endocrine Therapies Expand Options for Advanced Prostate Cancer

March 18th 2013

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

Trials Should Test Combinations, Sequences of Novel Treatments for Prostate Cancer

March 18th 2013

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

Dr. Gomella on Surrogate Endpoints in Prostate Cancer

March 18th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

Changing Paradigms-Integrating Novel Therapeutics Into the Standard of Care

April 18th 2011

Prostate cancer affects 1 of every 6 men in the United States

Considerations for Integrating Chemotherapy

April 18th 2011

Traditional, linear regimen of prostate cancer treatment may need to be reexamined as oncologists learn new ways to incorporate new therapies

Bone-Targeted Therapeutics

April 18th 2011

Initial clinical findings indicate that results with radiotherapies sometime improve when combined with immunotherapy

Immunotherapies: Avoiding collisions once the brake is released

April 13th 2011

Immunotherapies again made headlines in oncology last month

Novel Hormone-Radiation Therapy Approaches

April 12th 2011

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized high-risk prostate cancer patients

PSA: To Screen or Not to Screen

April 12th 2011

Screening for prostate cancer does work, despite controversy about its efficacy, according to IPCC Co-chair Leonard G. Gomella

Integrating New Hormonal Therapies in Advanced Disease

April 11th 2011

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

Novel vaccine approaches: Prospects for PROSTVAC®-VF are bright

April 11th 2011

As research into novel vaccine approaches for treating advanced prostate cancer continues...

The Overtreatment of Prostate Cancer

April 11th 2011

Increased prostate cancer screening has led to overtreatment and has not significantly reduced mortality rates in prostate cancer

Dr. Crawford on Moving Prostate Cancer Field Forward

April 7th 2011

Dr. Gomella Discusses Interdisiplinary Treatment

April 6th 2011